表紙
市場調查報告書
商品編碼
1021757

全球乾眼症市場預測(2021-2028)

Global Dry Eye Disease Market Forecast 2021-2028

出版日期: | 出版商: Inkwood Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在 2021 年至 2028 年的預測期內,全球乾眼症市場預計將以 5.76% 的複合年增長率增長。市場的增長被認為是由於乾眼症有前景的管道產品的推出、乾眼症新診斷技術的引入以及各年齡段干眼症發病率的增加等因素造成的。

準確診斷乾眼症非常重要。眼科領域取得了技術進步,在該市場運營的主要公司不斷專注於開發新的治療和診斷試劑。強生公司的子公司 Tear Science 向市場推出了最先進的干眼症診斷系統 LipiView II 眼表乾涉儀。

本報告調查了全球乾眼症市場,包括市場規模和預測、增長和製約因素、機遇和挑戰、按類型、最終用戶、應用和地區、提供的產品/服務進行的市場分析,它提供了有關近期戰略的信息發展、競爭條件、主要公司的簡介等。

目錄

第一章調查範圍和調查方法

  • 調查目的
  • 調查範圍
  • 調查方法
  • 先決條件和限制

第 2 章執行摘要

  • 市場規模/估計
  • 市場概覽

第三章市場動態

  • 主要增長因素
    • 乾眼症新診斷方法介紹
    • 推出有前景的干眼症管道產品
    • 不同年齡組乾眼症的發生率和患病率
  • 主要製約因素
    • 滴眼液引起副作用的風險
    • 替代療法的可及性
    • 乾眼專用產品成本高

第四章主要分析

  • COVID-19 對乾眼症市場的影響
  • 趨勢
  • 波特五力分析
  • 市場機會矩陣
  • 供應商情況

第 5 章按類型劃分的市場

  • 場外交易
  • 處方

第 6 章按產品劃分的市場

  • 消炎藥
    • 環孢素
    • 皮質類固醇
    • 其他消炎藥
  • 人工淚液
  • 淚點塞
  • 秘書
  • 其他產品

第 7 章按分銷渠道劃分的市場

  • 醫院藥房
  • 獨立藥房/藥店
  • 網上藥店

第八章區域分析

  • 北美
    • 市場規模/估計
    • 主要增長推動因素
    • 主要問題
    • 主要公司
    • 國家分析
  • 歐洲
    • 市場規模/估計
    • 主要增長推動因素
    • 主要問題
    • 主要公司
    • 國家分析
  • 亞太地區
    • 市場規模/估計
    • 主要增長推動因素
    • 主要問題
    • 主要公司
    • 國家分析
  • 其他領域
    • 市場規模/估計
    • 主要增長推動因素
    • 主要問題
    • 主要公司
    • 區域分析

第9章競爭形勢

  • 主要戰略發展
    • 併購
    • 產品發佈和開發
    • 聯盟與契約
    • 業務擴展、公告和銷售
  • 公司簡介
    • ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • BAUSCH HEALTH COMPANIES INC
    • ESW VISION
    • JOHNSON & JOHNSON
    • LUMENIS
    • NICOX SA
    • NOVARTIS AG
    • OASIS MEDICAL
    • OTSUKA HOLDINGS CO LTD
    • SANTEN PHARMACEUTICAL CO LTD
    • SUN PHARMACEUTICAL INDUSTRIES LTD
    • SENTISS PHARMA PVT LTD
    • URSAPHARM ARZNEIMITTEL GMBH
    • VISUFARMA
目錄
Product Code: 39637

KEY FINDINGS

The global dry eye disease market is forecasted to record a CAGR of 5.76% during the projected period of 2021 to 2028. The market growth is ascribed to factors such as the launch of promising pipeline products for dry eye disease, the introduction of new diagnostic techniques for dry eye disease, and the increasing incidence of dry eye among different age groups.

MARKET INSIGHTS

Dry eye is a chronic syndrome, progressive depending on the severity and cause. It is a condition when a person does not have tears to lubricate their eyes. Tears are a vital part of maintaining good eye health and assist in ensuring good vision. The syndrome is typically witnessed among older people. However, it is also becoming common among people who spend long hours in front of the computer.

The accurate diagnosis of dry eye disease is pivotal. Whether it is a practice focusing on a subspecialty, such as glaucoma and retina, or a primary anterior segment practice, the symptoms and signs of dry eye disease are widespread across modern lifestyles. Technological advancements are being made in the field of ophthalmology. Leading firms operating in the market continually concentrate on developing novel therapeutics and diagnostics, as well. For instance, TearScience, a subsidiary of Johnson & Johnson, introduced the latest diagnostic system for dry eye disease in the market, named LipiView II Ocular Surface Interferometer.

REGIONAL INSIGHTS

The global dry eye disease market growth evaluation entails the assessment of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecasting years due to the increasing number of ophthalmologists in countries like China, India, and Japan, providing good treatment and diagnostic services for ophthalmic conditions and the growing ophthalmic education.

COMPETITIVE INSIGHTS

Significant competition exists between key market players for the development of a new treatment for dry eye disease. The highly sustainable competitive advantages through innovation are likely to intensify rivalry among firms. Besides, solid strategies are anticipated to raise the competition in the market studied.

The top companies operating in the market are Johnson & Johnson, Allergan PLC (Acquired by Abbvie), Bausch Health Companies Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE (DED)
    • 3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE (DED)
    • 3.1.3. INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. RISK OF SIDE EFFECTS CAUSED BY EYE DROPS
    • 3.2.2. ACCESSIBILITY OF SUBSTITUTE THERAPIES
    • 3.2.3. HIGH COST OF SPECIALTY DRY EYE PRODUCTS

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON DRY EYE DISEASE MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. THREAT OF NEW ENTRY
    • 4.3.2. THREAT OF SUBSTITUTION
    • 4.3.3. BUYERS POWER
    • 4.3.4. SUPPLIERS POWER
    • 4.3.5. COMPETITIVE RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE

5. MARKET BY TYPE

  • 5.1. OTC
  • 5.2. PRESCRIPTION

6. MARKET BY PRODUCT

  • 6.1. ANTI-INFLAMMATORY DRUGS
    • 6.1.1. CYCLOSPORINE
    • 6.1.2. CORTICOSTEROID
    • 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
  • 6.2. ARTIFICIAL TEARS
  • 6.3. PUNCTAL PLUGS
  • 6.4. SECRETAGOGUES
  • 6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

  • 7.1. HOSPITAL PHARMACIES
  • 7.2. INDEPENDENT PHARMACIES AND DRUG STORES
  • 7.3. ONLINE PHARMACIES

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. KEY GROWTH ENABLERS
    • 8.1.3. KEY CHALLENGES
    • 8.1.4. KEY PLAYERS
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. KEY GROWTH ENABLERS
    • 8.2.3. KEY CHALLENGES
    • 8.2.4. KEY PLAYERS
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. GERMANY
      • 8.2.5.2. FRANCE
      • 8.2.5.3. UNITED KINGDOM
      • 8.2.5.4. ITALY
      • 8.2.5.5. RUSSIA
      • 8.2.5.6. BELGIUM
      • 8.2.5.7. POLAND
      • 8.2.5.8. REST OF EUROPE
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. KEY GROWTH ENABLERS
    • 8.3.3. KEY CHALLENGES
    • 8.3.4. KEY PLAYERS
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.2. JAPAN
      • 8.3.5.3. INDIA
      • 8.3.5.4. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5. SOUTH KOREA
      • 8.3.5.6. INDONESIA
      • 8.3.5.7. THAILAND
      • 8.3.5.8. SINGAPORE
      • 8.3.5.9. REST OF ASIA-PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. KEY GROWTH ENABLERS
    • 8.4.3. KEY CHALLENGES
    • 8.4.4. KEY PLAYERS
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 9.2.2. BAUSCH HEALTH COMPANIES INC
    • 9.2.3. ESW VISION
    • 9.2.4. JOHNSON & JOHNSON
    • 9.2.5. LUMENIS
    • 9.2.6. NICOX SA
    • 9.2.7. NOVARTIS AG
    • 9.2.8. OASIS MEDICAL
    • 9.2.9. OTSUKA HOLDINGS CO LTD
    • 9.2.10. SANTEN PHARMACEUTICAL CO LTD
    • 9.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
    • 9.2.12. SENTISS PHARMA PVT LTD
    • 9.2.13. URSAPHARM ARZNEIMITTEL GMBH
    • 9.2.14. VISUFARMA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE
  • TABLE 2: GERIATRIC POPULATION ACROSS DIFFERENT REGIONS (60 YEARS & ABOVE)
  • TABLE 3: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL OTC MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL OTC MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL PRESCRIPTION MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL PRESCRIPTION MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 12: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL CYCLOSPORINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL CYCLOSPORINE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL CORTICOSTEROID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL CORTICOSTEROID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL OTHER ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: GLOBAL ARTIFICIAL TEARS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 24: GLOBAL PUNCTAL PLUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL SECRETAGOGUES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 26: GLOBAL SECRETAGOGUES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 27: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 30: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 31: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 32: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 33: GLOBAL INDEPENDENT PHARMACIES AND DRUG STORES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 34: GLOBAL INDEPENDENT PHARMACIES AND DRUG STORES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 35: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 36: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 37: GLOBAL DRY EYE DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 38: GLOBAL DRY EYE DISEASE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 39: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 40: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 41: LEADING PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
  • TABLE 42: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 43: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 44: LEADING PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
  • TABLE 45: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 46: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 47: LEADING PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET
  • TABLE 48: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, HISTORIC YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 49: REST OF WORLD DRY EYE DISEASE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 50: LEADING PLAYERS OPERATING IN REST OF WORLD DRY EYE DISEASE MARKET
  • TABLE 51: LIST OF MERGERS & ACQUISITIONS
  • TABLE 52: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 53: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 54: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: GLOBAL DRY EYE DISEASE MARKET, BY TYPE, IN 2020
  • FIGURE 6: GLOBAL DRY EYE DISEASE MARKET, BY OTC, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL DRY EYE DISEASE MARKET, BY PRODUCT, IN 2020
  • FIGURE 9: GLOBAL DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2021-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY CYCLOSPORINE, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY CORTICOSTEROID, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL ANTI-INFLAMMATORY DRUGS MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2021-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2021-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2021-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, IN 2020
  • FIGURE 18: GLOBAL DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2021-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUG STORES, 2021-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 22: THE UNITED STATES DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 23: CANADA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 24: EUROPE DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 25: GERMANY DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 26: FRANCE DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 27: THE UNITED KINGDOM DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: ITALY DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 29: RUSSIA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: BELGIUM DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: POLAND DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: REST OF EUROPE DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: ASIA-PACIFIC DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 34: CHINA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: JAPAN DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 36: INDIA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 38: SOUTH KOREA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 39: INDONESIA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 40: THAILAND DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 41: SINGAPORE DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 42: REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 43: REST OF WORLD DRY EYE DISEASE MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 44: LATIN AMERICA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: MIDDLE EAST & AFRICA DRY EYE DISEASE MARKET, 2021-2028 (IN $ MILLION)